Image source: Getty Images.
Shares of Novo Nordisk A/S (NYSE: NVO), a leading diabetes care drugmaker, fell 10.2% in September, according to data from S&P Global Market Intelligence. Increased pressure in the U.S. to control prescription-drug price inflation reignited fear of shrinking profits ahead.